Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1625 1629 1631 1692
This examiner grants 60% of resolved cases
Connor Kennedy English operates within Tech Center 1600 and Art Unit 1625, having overseen 50 resolved cases. The examiner maintains an allowance rate of 60.0 percent, indicating a moderate path to patent issuance. For applications that reach allowance, the median days to allowance is 1256, providing a specific benchmark for prosecution timing in this art unit.
A standout metric for this examiner is the 51.3 percent interview lift. This high figure suggests that direct communication is an exceptionally effective strategy for overcoming rejections. The 51.3 percent lift is a significant data point for this profile, implying that interviews may be the most efficient way to resolve outstanding issues. Practitioners should consider scheduling an interview early in the process to leverage this high success rate.
Although the 50 resolved cases represent a smaller sample size, the 60.0 percent allowance rate offers a clear indication of the examiner's general disposition. The 1256 median days to allowance suggests a standard duration for the examination process. By focusing on the high interview lift, applicants can potentially navigate the 1625 Art Unit more effectively.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18078269 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | Final Rejection | Deciphera Pharmaceuticals, LLC |
| 18705770 | HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS | Non-Final OA | Merck Patent GmbH |
| 17821931 | COMPOUNDS WITH ANTI-TUMOR ACTIVITY AGAINST CANCER CELLS BEARING EGFR OR HER2 EXON 20 MUTATIONS | Non-Final OA | Board of Regents, The University of Texas System |
| 18559859 | DOSING REGIMENS | Non-Final OA | Novartis AG |
| 18835778 | SMALL MOLECULE PIM AND MTOR KINASE INHIBITOR AND METHODS OF USE THEREOF | Non-Final OA | Arizona Board of Regents on Behalf of the University of Arizona |
| 18689031 | PROTEIN DEGRADATION COMPOUND BASED ON NAMPT TARGET PROTEIN AND APPLICATION THEREOF | Non-Final OA | ShanghaiTech University |
| 18685603 | POSITIVE NMDA-MODULATING COMPOUNDS AND METHODS OF USE THEREOF | Non-Final OA | Sage Therapeutics, LLC |
| 18209515 | ADHESIVE PHOTOPROTECTIVE COMPOUNDS AND USES THEREOF | Non-Final OA | SKINOSIVE |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy